# Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea

> **NCT03761134** · PHASE3 · TERMINATED · sponsor: **Sanofi** · enrollment: 377 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** sotagliflozin (SAR439954)
- **DRUG:** placebo
- **DRUG:** metformin
- **DRUG:** sulfonylurea

## Key facts

- **NCT ID:** NCT03761134
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-30
- **Primary completion:** 2020-04-29
- **Final completion:** 2020-04-29
- **Target enrollment:** 377 (ACTUAL)
- **Why stopped:** Sanofi ended collaboration with Lexicon for Sotagliflozin. In China no regulatory pathway to transfer sponsorship during the conduct of ongoing studies.
- **Last updated:** 2022-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03761134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03761134, "Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT03761134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*